SEC Form 4 · accession 0001209191-18-040937
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil Bodick
Officer — Chief Scientific Officer
Period of report
Jul 2, 2018
Accepted (ET)
Jul 3, 2018 · 4:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 2, 2018 | S | 33,508 | $25.1042 | D | 78,799 | D | |
| Common Stock | Jul 3, 2018 | S | 16,492 | $25.00 | D | 62,307 | D | |
| Common Stock | holding | — | — | — | 1,000 | I | By spouse | |
| Common StockF3 | holding | — | — | — | 388,683 | I | By Versant Development Fund III, LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted May 31, 2018.
- F2The weighted average sale price for the transaction reported was $25.104229, and the range of prices were between $25 and $25.57. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F3The shares are held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.